Red biotechnology is the application of biotechnology in biopharmaceuticals and pharmaceuticals production. It provides patients with innovative and modern modes of diagnostics and treatments.
In 2018, the global Red Biotechnology market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Red Biotechnology status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Red Biotechnology development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Amgen
Beijing Tiantan Biological Products Co.
Biogen Idec
Cephalon
Chiron Corporation
CSL Limited
Genentech
Genzyme Corporation
Gilead Sciences
MedImmune LLC
Serono SA
Shenyang Sunshine Pharmaceutical Co.

Market segment by Type, the product can be split into
Gene Recombinant Drugs
Human Vaccines
Blood Products
Diagnostics Reagents
Others

Market segment by Application, split into
Drug Discovery
Drug Production
Gentic Testing
Pharmacogenomics
Gene Therapy

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Red Biotechnology status, future forecast, growth opportunity, key market and key players.
To present the Red Biotechnology development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Red Biotechnology are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.